

far as it can be concluded from Table 3, the rise in CK-MB mainly occurred between 6 and 24 h post-operatively, which is delayed in respect to the nicorandil patients for mitral valve replacement where the peak is at 6 h postoperatively. You conclude that these patients receiving nicorandil had a lower incidence of significant elevation of postoperative myocardial damage, suggesting that ongoing myocardial injury in the postoperative period might possibly be due to reperfusion injury and that nicorandil may have attenuated this due to its anti-inflammatory property. This could be correct but is in contrast to the finding that four nicorandil CABG patients compared to two placebo CABG patients had significantly elevated CK-MB levels. Theoretically, the incidence of significantly elevated CK-MB levels should be lower in the nicorandil group. Nonetheless, this could mean that there are multifactorial causes for postoperative myocardial infarction in your patients. When did the myocardial infarction actually happen in both groups and could other factors have been responsible such as the quality of coronary vessels? In addition, could postoperative factors rather than peri-operative management have influenced the occurrence of postoperative infarction in the cases you mentioned? Unfortunately, the limited number of patients in your study precludes any conclusion on this issue. Ideally, troponin I should also have been measured. Nevertheless, the general outcome in your publication is favourable for the use of nicorandil during cardioplegia.

Just as a remark, because enzymes of the potassium channel openers work more efficiently during normothermia, warm cardioplegia could have improved results due to increased potassium permeability leading to rapid sinus node arrest. In addition, Cohen and colleagues [6] concluded that terminal infusion of warm blood cardioplegia repleted myocardial ATP levels and improved postoperative myocardial function. In general, hypothermic cardioplegia should be avoided because

it can trigger CAS, thereby inducing ventricular fibrillation leading to depletion of myocardial ATP. Warm cardioplegia was not applied in your study. On the other hand, CK-MB levels under cold cardioplegia were improved in mitral valve replacement patients with nicorandil, which make your results even more interesting because CAS is more enhanced by hypothermia.

In spite of above remarks, we want to congratulate Chinnan and co-workers for their excellent paper which brings us one step further ahead to optimize coronary blood flow during CPB and thereby decreasing events of myocardial ischaemia.

G. Kiss, G. Gueret, O. Corre  
R. Deredec, C. C. Arvieux  
University Hospital of Brest  
Anaesthesia and Surgical Intensive Care  
Bd. Tanguy Prigent, France

## References

1. Chinnan NK, Puri GD, Thingnam SK. Myocardial protection by nicorandil during open-heart surgery under cardiopulmonary bypass. *Eur J Anaesthesiol* 2007; 24: 26–32.
2. Lopez JR, Jahangir R, Jahangir A, Shen WK, Terzic A. Potassium channel openers prevent potassium-induced calcium loading of cardiac cells: possible implications in cardioplegia. *J Thorac Cardiovasc Surg* 1996; 112: 820–831.
3. Nishizaki M, Arita M, Sakurada H *et al.* Induction of polymorphic ventricular tachycardia by programmed ventricular stimulation in vasospastic angina pectoris. *Am J Cardiol* 1996; 77: 355–360.
4. Iida R, Yazaki S, Saeki S, Ogawa S. Recurrent ST-segment elevations in a patient without significant coronary disease. *Clin Anesth* 2005; 17: 372–378.
5. Mehta AC, Rafanan AL, Bulkley R, Walsh M, DeBoer GE. Coronary spasm and cardiac arrest from carcinoid crisis during laser bronchoscopy. *Chest* 1999; 115: 598–600.
6. Cohen G, Borger MA, Weisel RD, Rao V. Intraoperative myocardial protection: current trends and future perspectives. *Ann Thorac Surg* 1999; 68: 1995–2001.

## Reply

doi: 10.1017/S0265021507002633

### EDITOR:

We thank Kiss and colleagues for their valuable comments. The faster onset of electromechanical

arrest after administration of cardioplegia is very likely due to the coronary vasodilating properties of nicorandil [1]. Coronary vasodilatation could have also resulted in better distribution of the cardioplegic solution and improved myocardial preservation and, hence, fewer arrhythmias while coming off cardiopulmonary bypass (CPB) and less risk of postoperative myocardial infarction. The increased incidence of

Correspondence to: Nevin Kollannoor Chinnan, The Canberra Hospital, PO Box-11, Woden, ACT, Australia. E-mail: nevinke2001@yahoo.com; Tel: +61 424486052; Fax: +61 262443300

Accepted for publication 27 July 2007 EJA 4612A  
First published online 13 September 2007

myocardial infarction in the nicorandil group coronary artery bypass grafting (CABG) patients could be multifactorial. However, it is interesting to note that three out of four patients who had a post-operative myocardial infarction in the nicorandil group, CABG patients were diabetics. Our study did not look into coronary artery spasms in the post-operative period. In this context, we would like to refer to a case report where nicorandil infusion was used to manage distal micro-vascular spasm characterized by ST segment elevation in the electrocardiogram, serially elevated cardiac enzymes (creatinine kinase and creatine phosphokinase-MB) and new onset regional wall motion abnormalities in the absence of fixed or vasospastic occlusion of coronary vessels on angiography [2]. With regard to reperfusion injuries and arrhythmias, intravenous and intracoronary nicorandil have been shown to be of benefit after percutaneous coronary interventions for acute myocardial infarctions [3,4]. After prolonged cardioplegic arrest (4 h) in an isolated rabbit heart model, nicorandil was found to attenuate ischaemia-reperfusion injury of the myocardium and coronary endothelium, and ameliorate leukocyte activation [5]. These findings by other researchers are in accordance with our observations. We would also like to clarify that we used a terminal infusion of warm blood cardioplegia (hot shots) before coming off CPB as it is the present day standard of care and apologize for not making that clear in our study protocol. We fully agree with Kiss and colleagues that a larger multi-centre randomized controlled trial is required to determine the efficacy and the role of nicorandil in certain subclasses of patients like those developing coronary artery spasms in the postoperative period, and diabetics undergoing cardiac surgery.

N. K. Chinnan  
The Canberra Hospital  
Woden, ACT  
Australia

G. D. Puri  
Department of Anaesthesia and Intensive Care  
Post Graduate Institute of Medical Education and  
Research (PGIMER)  
Chandigarh, India

S. K. S. Thingnam  
Department of Cardiothoracic and Vascular Surgery  
Post Graduate Institute of Medical Education and  
Research (PGIMER)  
Chandigarh, India

## References

1. Chinnan NK, Puri GD, Thingnam SKS. Myocardial protection by nicorandil during open heart surgery under cardiopulmonary bypass. *Eur J Anaesthesiol* 2007; 24: 26–32.
2. Mizogami M, Shimo K, Taguchi T, Horita Y. Stunned myocardium after hip arthroplasty. *Br J Anaesth* 2000; 84: 510–513.
3. Takarabe K, Okazaki Y, Higuchi S, Murayama J, Natsuaki M, Itoh T. Nicorandil attenuates reperfusion injury after long cardioplegic arrest. *Asian Cardiovasc Thorac Ann* 2007; 15: 204–209.
4. Ota S, Nishikawa H, Takeuchi M *et al.* Impact of nicorandil to prevent reperfusion injury in patients with acute myocardial infarction: Sigmart Multicenter Angioplasty Revascularization Trial (SMART). *Circ J* 2006; 70: 1099–1104.
5. Hara H, Horinaka S, Yabe A *et al.* Suppressive effect of nicorandil in ventricular arrhythmias after reperfusion therapy in patients with acute myocardial infarction. *J Cardiol* 2007; 49: 135–141.